NASDAQ:SCNX Scienture Q1 2026 Earnings Report $0.45 +0.04 (+10.00%) Closing price 08/12/2026 04:00 PM EasternExtended Trading$0.41 -0.04 (-8.67%) As of 08:41 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast Scienture EPS ResultsActual EPS-$0.08Consensus EPS -$0.23Beat/MissBeat by +$0.15One Year Ago EPSN/AScienture Revenue ResultsActual Revenue$0.06 millionExpected Revenue$0.40 millionBeat/MissMissed by -$344.68 thousandYoY Revenue GrowthN/AScienture Announcement DetailsQuarterQ1 2026Date5/15/2026TimeAfter Market ClosesConference Call DateFriday, May 15, 2026Conference Call Time8:00AM ETUpcoming EarningsScienture's Q2 2026 earnings is estimated for Monday, August 17, 2026, based on past reporting schedules, with a conference call scheduled at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Q2 2026 Earnings ReportConference Call ResourcesQuarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsQuarterly report(10-Q) Scienture Earnings HeadlinesScienture Holdings Stock Price HistoryAugust 12 at 6:43 PM | investing.comScienture launches Rezenopy as second FDA-approved commercial productAugust 12 at 6:43 PM | msn.comReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and stinging losses? Dave Aquino is giving away the exact 11-hour options strategy he uses in volatile markets. You get the plain English blueprint behind the strategy and the very same "rinse and repeat" ticker he's traded nearly 900 times with a 95.3% success rate. It's so simple to understand, you could trade it tomorrow.August 13 at 1:00 AM | Base Camp Trading (Ad)SCIENTURE Announces Commercial Launch and Fulfillment of Initial Purchase Orders of REZENOPY™, the Highest Dose FDA-Approved Naloxone Nasal SprayAugust 12 at 8:05 AM | globenewswire.comScienture Holdings stock jumps over 20% pre-market: Here's whyJuly 10, 2026 | msn.comSCIENTURE Announces Commercial Inventory Readiness and July Shipments of REZENOPY™ (naloxone hydrochloride) to WholesalersJuly 9, 2026 | finance.yahoo.comSee More Scienture Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Scienture? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Scienture and other key companies, straight to your email. Email Address About ScientureScienture (NASDAQ:SCNX) engages in the provision of health services and pharmaceutical products. It focuses on addressing underserved patients and indications through novel product concepts and innovation. The company was founded on July 15, 2005 and is headquartered in Lutz, FL.View Scienture ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Franco-Nevada Earnings: Gold Is Rallying, But Does the Stock Even Care?Nebius’ Q2 Beat Shows the AI Bottleneck Is Capacity, Not DemandCoreWeave's $129 Billion AI Backlog Changes the Bull CaseGE Vernova’s AI Power Boom Faces a Profit TestCardinal Health Earnings: Can Perfection Get Priced In Twice?Legacy Jet Builders Stall While Embraer Accelerates to New HighsFastly’s Q2 Rally Shows Investors Are Buying the Edge AI Turnaround Upcoming Earnings BHP Group (8/17/2026)Palo Alto Networks (8/17/2026)Home Depot (8/18/2026)Medtronic (8/18/2026)Keysight Technologies (8/18/2026)Lowe's Companies (8/19/2026)TJX Companies (8/19/2026)Target (8/19/2026)Analog Devices (8/19/2026)NetEase (8/20/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
